Skip to content

PTHS PTHS ZELSUVMI Royalty Agreement — Convertible fees allocated to royalty

Similar metrics at other companies

Syndax Pharmaceuticals logo
SNDXRoyalty Interest Financing Less Current Portion
$343.91M+3.7%
Alkermes logo
ALKSVumerity — Percentage Of Net Sales In Royalty Payment
3.8%0.0pp
Xencor logo
XNCRRoyalties — Expected royalty interest payments
$12M
PVL
PVLARoyalty Agreement Liability
$19.8M+50.5%
Esperion Therapeutics logo
ESPRRoyalty sale liability
$80.75M+41.1%
Alpha Cognition logo
ACOGRevaluationof Conversion Feature Liability
$519.11K

Other financials

Income statement

See full
Revenue$10.9M
Gross profit$9.2M
Operating income-$13.1M-614%
Net income-$10.2M-420%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K
Free cash flow-$13.3M-2,008%

Valuation

See full
Market cap$98.22M+75.4%
Enterprise value$95.89M
P/S3.6×

Profitability

See full
Gross margin79.6%
Operating margin-157.7%
Net margin-186.2%
FCF margin-60.8%

Returns & leverage

See full
Return on equity-333.8%
Debt / equity0.8×
Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept pths:ContractualObligationLiabilityConvertibleFeesAllocatedToRoyalty.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's zelsuvmi royalty agreement — convertible fees allocated to royalty.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTHS's ZELSUVMI royalty agreement — convertible fees allocated to royalty?
PTHS (PTHS) reported ZELSUVMI royalty agreement — convertible fees allocated to royalty of $0 in Q1 2026.
What does ZELSUVMI royalty agreement — convertible fees allocated to royalty mean?
This metric represents the portion of upfront or milestone-based fees that have been reclassified or allocated to royalty obligations under a licensing agreement. It reflects the accounting treatment of non-recurring payments that are amortized or recognized against future royalty streams. This helps investors understand how initial capital outlays are integrated into the ongoing cost structure of a product segment.